Dr. Reddy's Laboratories Limited is a global integrated pharmaceutical company that consists of multiple segments that manufacture and market prescription and over-the-counter finished pharmaceutical products, as well as active pharmaceutical ingredients and intermediates, contract research services, and biologics. Its Proprietary Products segment focuses on the research and development of differentiated formulations while the Others segment develops therapies mainly in the fields of oncology and inflammation for various medical categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, respiratory, stomatology, urology, and nephrology. They have a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets.